+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gonorrhea: Market View

  • PDF Icon

    Report

  • 118 Pages
  • October 2026
  • Region: Global
  • GlobalData
  • ID: 6290944

Gonorrhea: Market View

Summary

This report provides a data-driven overview of the current and future competitive landscape in Gonorrhea Therapeutics.
  • In 2025, there were more than 2.75 million diagnosed incident cases of GC in the 16 countries covered in the analyst’s epidemiology forecast.
  • The GC market remains largely generic, with approved treatments spanning several antibiotic classes including penicillin antibiotics, sulfonamides, fluoroquinolones, tetracyclines, azalide derivatives, aminopenicillins, and macrolides.
  • Treatment has evolved from fluoroquinolone monotherapy to ceftriaxone-azithromycin dual therapy and, since 2020, ceftriaxone 500 mg IM monotherapy, which remains the recommended first-line treatment in 2026.
  • Newly approved oral agents GSK’s Blujepa (gepotidacin) and Innoviva’s Nuzolvence (zoliflodacin) expand options and may help address AMR, but are currently limited to uncomplicated urogenital GC.
  • The GC pipeline holds 42 molecules with no assets in the Pre-registration and Phase II stages, two assets in Phase III development, and three assets in Phase I development.
  • Over the past decade, 404 clinical trials have been conducted in GC. The year with the most studies initiated was 2018, with 75 trials, followed by 2021.
  • Over the past 10 years, acquisitions dominated GC product deals in South America (100.0%), Asia-Pacific (56.4%), Europe (41.5%), North America (37.8%), and the Middle East and Africa (27.3%). Licensing was most common in the Middle East and Africa (36.4%), while mergers were concentrated in North America (13.3%), Asia-Pacific (6.4%), and Europe (3.8%); none were recorded in South America or the Middle East and Africa.
  • Key opinion leaders agree that expanded screening has shifted gonorrhea diagnoses toward asymptomatic disease, creating persistent diagnosis-to-treatment delays across care settings. While ceftriaxone remains trusted for high cure rates (95-98%), its intramuscular administration severely limits treatment convenience, and existing oral alternatives provide inadequate efficacy and coverage.
  • Consequently, clinicians emphasize an urgent need for an affordable, single-dose oral regimen delivering at least 95% efficacy across all anatomical sites to outrun inevitable antimicrobial resistance. Beyond therapeutics, experts identify rapid, resistance-predicting point-of-care diagnostics and effective partner treatment as critical structural priorities to prevent reinfection and curb transmission.

Scope

The analyst’s Gonorrhea: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule type
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Gonorrhea Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Reflux Esophagitis (Gastroesophageal Reflux Disease)Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview of Drugs by Approval and Drug Type
4.3 Overview of Drugs by Molecule Type
4.4 Overview of Drugs by MOA
4.5 Product Profile and Sales Forecast
5 Unmet need6 Pricing and Reimbursement Assessment
7 Pipeline Drugs Assessment
7.1 Pipeline Drugs
7.2 Overview by Development Stage
7.3 Overview by Mechanism of Action
7.4 Overview by Molecule Type
7.5 Overview by Route of Administration
7.6 Product Profile and Sales Forecast
7.7 Drug-specific PTSR and LoA
7.8 Indication-specific and Therapy Area-specific PTSR and LoA
8 Clinical Trials Assessment
8.1 Historical Overview
8.2 Overview by Phase
8.3 Overview by Status
8.4 Overview by Phase for Ongoing and Planned Trials
8.5 Trials with Virtual Components
8.6 Top 20 Biomarkers by Trial Phase
8.7 Overview of Trials by Geography
8.8 Single-Country and Multinational Trials by Region
8.9 Top 20 Sponsors with Breakdown by Phase
8.10 Top 20 Sponsors with Breakdown by Status
8.11 Overview by Endpoint Status
8.12 Overview by Race and Ethnicity
8.13 Enrollment Data
8.14 Top 20 countries for Trial Sites
8.15 Top 20 Sites Globally
8.16 Feasibility Analysis - Geographic Overview
8.17 Feasibility Analysis - Benchmark Models
9 Deals Landscape
9.1 Mergers, Acquisitions, and Strategic Alliances by Region
9.2 Recent Mergers, Acquisitions, and Strategic Alliances
10 Commercial Assessment
10.1 Key Market Players
11 Future Market Catalysts
12 Appendix
12.1 Methodology
12.2 Methodology - Sales Forecast
12.3 Methodology - Pricing and Reimbursement
12.4 Methodology - PTSR and LoA Analysis
12.5 About the Authors
12.6 Contact Us
12.7 Disclaimer